Ioanna-Evdokia Galani

Dr. Ioanna-Evdokia Galani

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Immunity
Verified
Journal Article
Closed access
IGIoanna-Evdokia Galani
Ioanna-Evdokia Galani
VTVasiliki Triantafyllia
Vasiliki Triantafyllia
EEEvridiki-Evangelia Eleminiadou
Evridiki-Evangelia Eleminiadou
OKOurania Koltsida
Ourania Koltsida
ASAthanasios Stavropoulos
Athanasios Stavropoulos
V0VAT Number: EL 090050626
VAT Number: EL 090050626

4 December 2020 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
IGIoanna-Evdokia Galani
Ioanna-Evdokia Galani
NRNikoletta Rovina
Nikoletta Rovina
VLVicky Lampropoulou
Vicky Lampropoulou
VTVasiliki Triantafyllia
Vasiliki Triantafyllia
MMMaria Manioudaki
Maria Manioudaki
V0VAT Number: EL 090050626
VAT Number: EL 090050626

15 October 2008 in Cancer Research
Verified
Journal Article
Open access
PDF file
MWMarco Wendel
Marco Wendel
IGIoanna-Evdokia Galani
Ioanna-Evdokia Galani
ESElisabeth Suri-Payer
Elisabeth Suri-Payer
ACAdelheid Cerwenka
Adelheid Cerwenka
Several studies have correlated high numbers of tumor-infiltrating natural killer (NK) cells with a good prognosis for cancer patients. Our study aimed at identifying factors controlling intratumoral NK cell accumulation in s.c. injected NK cell sensitive tumor models and at studying their effect on survival time of recipient mice. We observed that fewer NK cells infiltrated the tumors in IFN-γ receptor knockout (IFN-γR−/−) mice compared with wild-type controls that correlated with decreased survival rate. Exogenous application of IFN-γ in the tumor augmented levels of ligands of the chemokine receptor CXCR3, increased NK cell accumulation, and prolonged survival. Furthermore, our data show that CD27high NK cells, which under steady-state conditions express CXCR3, preferentially accumulated in the tumor tissue. Accordingly, significantly lower numbers of tumor-infiltrating NK cells were detected in CXCR3−/− mice, and the capacity of adoptively transferred CXCR3−/− NK cells to accumulate in the tumor was severely impaired. Finally, exogenous application of the CXCR3 ligand CXCL10 in the tumor or ectopic expression of CXCL10 by tumor cells increased the numbers of NK cells in the tumors and prolonged NK cell–dependent survival. Our results identify IFN-γ and the expression of CXCR3 on NK cells as prerequisites for NK cell infiltration into tumors. Exploiting strategies to augment NK cell accumulation in the tumor might lead to the development of effective antitumor therapies. [Cancer Res 2008;68(20):8437–45]

9 July 2015 in Journal of Leukocyte Biology
Verified
Journal Article
Closed access
PDF file
IGIoanna-Evdokia Galani
Ioanna-Evdokia Galani
V0VAT Number: EL 090050626
VAT Number: EL 090050626
Neutrophils are the first immune cell population recruited to sites of infection, including viral infections, and exhibit both protective and pathologic functions. In antibacterial and antifungal immunity, the role of neutrophils is well defined. However, in antiviral immunity, much less is known. Conventional wisdom suggests that neutrophils enhance antiviral defenses, yet evidence for that is limited. Interaction with other immune cell populations, virus internalization and killing, the release of cytokines, chemokines, and antimicrobial components are all mechanisms by which neutrophils can contribute to pathogen clearance. NET formation, extensively studied during bacterial infection, can further mediate antiviral defense by trapping and inactivating virus. In the present review, we discuss the current understanding of the complex role of neutrophil immunity in viral infections and disease pathogenesis and the potential mechanisms identified to date. We pinpoint the importance of a finely tuned neutrophilic response for achieving effective immune protection while avoiding detrimental tissue damage that can form the basis for the development of novel therapeutics.

15 November 2008 in Blood
Verified
Journal Article
Open access
PDF file
NNNorman Nausch
Norman Nausch
IGIoanna-Evdokia Galani
Ioanna-Evdokia Galani
ESEva Schlecker
Eva Schlecker
ACAdelheid Cerwenka
Adelheid Cerwenka
Myeloid-derived suppressor cells (MDSCs) accumulate in cancer patients and tumor-bearing mice and potently suppress T-cell activation. In this study, we investigated whether MDSCs regu-late natural killer (NK)–cell function. We discovered that mononuclear Gr-1+CD11b+F4/80+ MDSCs isolated from RMA-S tumor-bearing mice do not suppress, but activate NK cells to produce high amounts of IFN-γ. Gr-1+CD11b+F4/80+ MDSCs isolated from tumor-bearing mice, but not myeloid cells from naive mice, expressed the ligand for the activating receptor NKG2D, RAE-1. NK-cell activation by MDSCs depended partially on the interaction of NKG2D on NK cells with RAE-1 on MDSCs. NK cells eliminated Gr-1+CD11b+F4/80+ MDSCs in vitro and upon adoptive transfer in vivo. Finally, depletion of Gr-1+ cells that comprise MDSCs confirmed their protective role against the NK-sensitive RMA-S lymphoma in vivo. Our study reveals that MDSCs do not suppress all aspects of antitumor immune responses and defines a novel, unexpected activating role of MDSCs on NK cells. Thus, our results have great impact on the design of immune therapies against cancer aiming at the manipulation of MDSCs.

1 February 2019 in Current Opinion in Immunology
Verified
Journal Article
Closed access
V0VAT Number: EL 090050626
VAT Number: EL 090050626
IZIvan Zanoni
Ivan Zanoni
IGIoanna-Evdokia Galani
Ioanna-Evdokia Galani